Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2022 07:30 ET | Source: Graybug Vision, Inc.

Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting

BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
January 07, 2021 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021

REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
November 12, 2020 16:05 ET | Source: Graybug Vision, Inc.

Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Recent Corporate Developments

REDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
September 25, 2020 08:00 ET | Source: Graybug Vision, Inc.

Graybug Appoints Three New Members to its Board of Directors

REDWOOD CITY, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
September 24, 2020 20:12 ET | Source: Graybug Vision, Inc.

Graybug Vision Announces Pricing of Upsized Initial Public Offering

REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
September 04, 2020 07:00 ET | Source: Graybug Vision, Inc.

Graybug Vision Appoints Robert Breuil as Chief Financial Officer

REDWOOD CITY, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (“Graybug”), a clinical stage biopharmaceutical company focused on developing transformative medicines to treat chronic...
May 18, 2020 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision Appoints Parisa Zamiri, Physician-Scientist with Deep Expertise in Ophthalmology, as Chief Medical Officer

REDWOOD CITY, Calif., May 18, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat vision-threatening...
March 18, 2020 07:00 ET | Source: Graybug Vision, Inc.

Graybug Vision Concludes Patient Enrollment in its Phase 2b Clinical Trial of GB-102 in Wet Age-Related Macular Degeneration and Accelerates Trial Read-out by Approximately Six Months

REDWOOD CITY, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat diseases of the...
February 28, 2020 07:00 ET | Source: Graybug Vision, Inc.

Graybug Vision Presents Preclinical Results for GB-401, a Potential Sustained-Delivery Treatment of up to Six Months for Primary Open Angle Glaucoma, at the American Glaucoma Society Annual Meeting

REDWOOD CITY, Calif., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc., a biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic...